Trial reportJournal of cancer research and clinical oncology2013
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
Trial report in Journal of cancer research and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.Journal of cancer research and clinical oncology · 2023Pooled it
- Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis.World journal of gastroenterology · 2019Pooled it
- Specific immunotherapy in hepatocellular cancer: A systematic review.Journal of gastroenterology and hepatology · 2017Pooled it
- Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.World journal of transplantation · 2025Review
- Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy.Cells · 2025Review
- Harnessing Dendritic Cell Function in Hepatocellular Carcinoma: Advances in Immunotherapy and Therapeutic Strategies.Vaccines · 2025Review
- Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances.Frontiers in immunology · 2025Review
- Review
- Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.Journal of clinical and translational hepatology · 2024Review
- Review
- Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies.Cancers · 2022Review
- Therapeutic efficacy of dendritic cell injection in advanced hepatocellular carcinoma: the role of natural killer and T lymphocytes.Clinical and experimental hepatology · 2022Article
- Immunotherapies for hepatocellular carcinoma.Cancer medicine · 2022Review
- Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.Frontiers in immunology · 2022Review
- Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.Life (Basel, Switzerland) · 2021Review
- Imaging in Tumor Immunology.Nuclear medicine and molecular imaging · 2021Review
- Targeting tumor-associated macrophages to synergize tumor immunotherapy.Signal transduction and targeted therapy · 2021Review
- Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.Cellular & molecular immunology · 2021Review
- [Advances in the study of cellular immunotherapy for liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundDendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines.
objectivesOur study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment.
methodsThirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done.
resultsImprovement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8(+) T cells and serum interferon gamma were elevated after DCs injection.
conclusionAutologous DC vaccination in advanced HCC patients is safe and well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.